Novel Anti-inflammatory Compounds - EP3759089A1
Summary
The European Patent Office published patent application EP3759089A1 for novel anti-inflammatory compounds developed by Inflazome Limited. The patent covers compounds classified under C07D 401/12 with therapeutic applications (A61P 29/00). Validated in designated contracting states including Germany, France, United Kingdom, Italy, Spain, and other EU member states.
What changed
The EPO published EP3759089A1, a patent application for novel anti-inflammatory compounds belonging to Inflazome Limited. The compounds are classified under IPC category C07D 401/12 with therapeutic applications (A61P 29/00) and pharmaceutical formulation (A61K 31/444).
For pharmaceutical manufacturers and drug developers, this patent represents potential freedom-to-operate considerations for anti-inflammatory drug development. Companies developing similar compounds or formulations should conduct prior art searches and assess potential infringement risks. The patent is validated in all designated EU contracting states, creating enforceable IP rights in those jurisdictions.
What to do next
- Monitor patent portfolio for freedom-to-operate implications
- Review compound claims for potential licensing opportunities
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NOVEL COMPOUNDS
Publication EP3759089A1 Kind: A1 Apr 08, 2026
Applicants
Inflazome Limited
Inventors
MILLER, David, VAN WILTENBURG, Jimmy, COOPER, Matthew
IPC Classifications
C07D 401/12 20060101AFI20190907BHEP A61P 29/00 20060101ALI20190907BHEP A61K 31/444 20060101ALI20190907BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.